Who is sponsoring NCT05909540?

NCT05909540 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT05909540?

Interventions in NCT05909540: Posterior facet distraction and fusion.

What condition does NCT05909540 study?

NCT05909540 studies Basilar Invagination.

Is NCT05909540 still recruiting?

NCT05909540 is currently status unknown. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT05909540

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Study of Natural History and Clinical Outcomes for Basilar Invagination

Status unknown Last updated 18 June 2023

What this trial tests

trial testing Posterior facet distraction and fusion in Basilar Invagination in 200 participants. Status unknown.

Timeline

6 February 2022

Primary endpoint
1 December 2023

30 June 2024

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	6 February 2022
Primary completion	1 December 2023
Estimated completion	30 June 2024
Sites	1 location across China

Drugs / interventions tested

Posterior facet distraction and fusion

Conditions studied

Basilar Invagination — all drugs for Basilar Invagination →

Sponsor

Xuanwu Hospital, Beijing

Who can join

Eligibility, any sex, with Basilar Invagination. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Prospective Study of Natural History and Clinical Outcomes for Basilar Invagination

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05909540 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing